AUTHORS
Morgan Walcheck, PhD, Caroline Schuster-Kubaczka2, Lu Yue, PhD3, Mindy Leder, MS4, Vivian Taylor5, Thorsten Schlaeger6, George Daley, MD, PhD7, Trista North, PhD8
AFFILIATIONS
1 Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States
4 Boston Children's Hospital, Boston, Massachusetts, United States
5 Boston Children's Hospital, Boston, Massachusetts, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States
7 Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
8 Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Despite recent advancements in iPSC to HSC generation protocols, only one in three million cells transplant successfully. Therefore, development of clinical-scale off-the-shelf therapies requires further elucidation of key spatiotemporal cues that promote or maintain cell fate. Sterile inflammatory signaling, mediated via “stress-responsive” activation of the NLRP3 Inflammasome by developmental fluctuations in embryonic metabolism, is an essential cue driving de novo hematopoietic stem cell (HSC) formation in the vertebrate embryo. While necessary for proliferative expansion to establish the lifelong stem cell pool, prolonged inflammatory exposure compromises stem cell maintenance and multipotency. Thus, the mechanisms regulating these inflammatory cascades to promote self-renewal, while preventing premature differentiation or exhaustion remain a fundamental, unresolved question. Here, we identify the Aryl Hydrocarbon Receptor (AHR), a pharmacologically targetable, self-regulating transcription factor, as a critical rheostat of NLRP3-mediated sterile inflammation within the embryonic niche microenvironment, where it functions to sustain HSC cell-state.
Utilizing a novel transgenic, real-time in vivo AHR activity reporter zebrafish line driven by conserved tandem xenobiotic response elements, we demonstrate that endogenous AHR activation is spatially restricted to the discrete endothelial cell "pockets” within secondary (2°) “expansion” niches [zebrafish: caudal hematopoietic tissue (CHT); functionally equivalent to the mammalian fetal liver]. Following specification in the embryonic dorsal aorta, newly emerged HSPCs migrate to these specialized AHR-active vascular microenvironments, and exhibit significantly prolonged physical retention and cell-to-cell contact compared to non-AHR-activated regions.
Mechanistic interrogation of this phenomenon revealed that AHR signaling is highly stage-dependent. Selective small-molecule activation of AHR during the developmental “expansion” window increased HSPC abundance by 21% (p< 0.005, n=10 embryos/clutch) in the 2° niche, which was sustained (p< 0.05, n=10 embryos/clutch) as cells colonized adult hematopoietic sites (zebrafish: kidney marrow; mammals: bone marrow), without perturbing lineage output, indicating a robust bias toward self-renewal. Notably, premature activation of AHR during the “specification” phase restricted HSPC development by 27% (p< 0.01, n=10 embryos/clutch), underscoring strict temporal requirements for this regulatory axis. In contrast to directed activation, pharmacological inhibition of AHR during the “expansion” phase depleted the HSPC pool by 14% (p<0.05, n=10 embryos/clutch), skewing cell fate toward premature differentiation of select myeloid and lymphoid cell-types.
AHR can directly regulate inflammatory activity, including transcription of the nlrp3 gene. To delineate the mechanism of AHR action on HSPC formation and function, we employed an established in vivo reporter of inflammasome activity (Tg(pycard:pycard-EGFP)), revealing precise reciprocal activity: AHR activators decreased inflammasome activation by 23% (p< 0.05, n=10 embryos/clutch), while inhibitors increased inflammatory state by 20% (p<0.05, n=10 embryos/clutch). Importantly, genetic ablation of key inflammasome components, pycard (ASC) or caspase-1, fully rescued these effects, confirming that AHR acts through strict upstream suppression of the NLRP3 inflammasome to modulate HSPC number.
Collectively, these findings indicate that localized AHR activation dynamically dampens developmental stress-responsive inflammatory signaling within expansion pockets of the vascular niche, providing a protective shield that balances HSPC self-renewal and maintenance, and blocks premature lineage commitment. Importantly, the role of AHR as a physiological inflammatory rheostat appears to be retained in later stages of hematopoietic differentiation: transient pharmacological inhibition of AHR activity at the pro-T cell stage during human induced pluripotent stem cell (iPSC) differentiation significantly augmented yield of CD4+ T cells by 44% (p<0.01, n=3 independent runs) in vitro. Together, our work establishes temporal modulation of the AHR-NLRP3 signaling axis as a pharmacologically amenable target to promote balanced expansion of the HSC pool, which may have direct implications for strategies to effectively drive patient-specific iPSCs toward iHSC production at clinical-scale for translational use.
DISCLOSURES
Morgan Walcheck, PhD: No relevant conflicts of interest to declare.